Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $7
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $9 to $7.
Leerink Partners analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $9 to $7.